Evidence map›Paper›PMID 41608029›Full record

ArticleBlood vessels, thrombosis & hemostasis2026

Treatment of canine hemophilia A via intraosseous delivery of a platelet-specific factor VIII-lentiviral vector.

Cameron W Rementer, Chong Li, Timothy C Nichols, Xiaohe Cai, Julia Joo, Xuefeng Wang, Mark Kloos, Nneka George, Ting-Yen Chao, Yuanyi Xu and 4 more

Abstract read
In one paragraph

Article in Blood vessels, thrombosis & hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Cameron W RementerCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA.
Chong LiCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA.
Timothy C NicholsDepartment of Pathology and Laboratory Medicine and Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Xiaohe CaiCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA.
Julia JooCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA.
Xuefeng WangCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA.
Mark KloosDepartment of Pathology and Laboratory Medicine and Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Nneka GeorgeDepartment of Pathology and Laboratory Medicine and Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Ting-Yen ChaoCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA.
Yuanyi XuCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA.
Mortimer PonczDivision of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA.
Hans D OchsCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA.
David J RawlingsCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA.
Carol H MiaoCenter for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA.

Funding

Intraosseous delivery of lentiviral vectors for hemophilia A gene therapyR01HL134321 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI Carol H Miao · 2016 to 2026
$6.2M
Ultrasound-mediated gene delivery to achieve therapeutic correction of hemophilia AR01HL151077 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI MIAO, CAROL H · 2020 to 2023
$3.2M
Gene Editing for Hemophilia A Treatment Using Lipid NanoparticlesR01HL169793 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI Carol H Miao · 2024 to 2026
$2.2M
Direct in vivo bone marrow transfer of lentiviral vector to correct hemophilia AR56HL123326 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI MIAO, CAROL H · 2014 to 2014
$485k
NHLBI NIH HHS R01 HL134321NHLBI NIH HHS R01 HL151077NHLBI NIH HHS R01 HL169793NHLBI NIH HHS R56 HL123326
6 · The paper itself

Abstract

Hemophilia A (HemA) is a genetic disease resulting from a factor VIII (FVIII) deficiency. Traditional protein infusions to treat HemA are costly and inconvenient and require repeated dosing. We demonstrated previously that intraosseous (IO) gene therapy via delivery of lentiviral vectors (LVs) into bone marrow targeting FVIII expression in platelets successfully treated HemA mice. To facilitate the translation of this novel strategy to clinical application, we investigated the treatment of HemA dogs using IO gene therapy. The vesicular stomatitis virus-pseudotyped G-cF8-LV incorporating a platelet-specific promoter, Gp1bα, and canine

Identifiers

PMID41608029
PMCPMC12835592

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.